VirginiaMKlimekMD

Oncology • New York, NY

Assistant Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Klimek is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Klimek's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10021
Phone+1 212-639-2000
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

Certifications & Licensure

NC State Medical License 2020 - 2022
NY State Medical License 1995 - 2022
NJ State Medical License 2015 - 2021

Clinical Trials

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Start of enrollment: 1999 Aug 01
Completed
Phase 1
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma Start of enrollment: 2002 May 01
Completed
Phase 2
An Open-Label, Phase II (Proof Of Concept) Trial Of PKC412 Monotherapy In Patients With Acute Myeloid Leukemia (AML) And Patients With High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Mar 01
A Multicenter, Single-Arm, Open-Label Study Of The Efficacy And Safety Of CC-5013 Monotherapy In RBC Transfusion-Dependent Subjects With Myelodysplastic Syndromes Start of enrollment: 2003 Sep 01
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Jul 01
Completed
Phase 1, Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Mar 01
Withdrawn
Phase 1, Phase 2
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Start of enrollment: 2011 May 01
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes Start of enrollment: 2014 Aug 27
Completed
Phase 2
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors Start of enrollment: 2017 Aug 07
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Tulasigeri M Totiger, Sana Chaudhry, Elgilda Musi, Jumana Afaghani, Skye Montoya, Frank Owusu-Ansah, Stanley Lee, Gary Schwartz, Virginia Klimek, Justin Taylor> ;Journal of Cellular and Molecular Medicine. 2023 Feb 1
40 citations
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Bernard, E., Tuechler, H., Greenberg, P., Hasserjian, R., Arango Ossa, J., Nannya, Y., Devlin, S., Creignou, M., Pinel, P., Monnier, L., Gundem, G., Medina-Martinez, J...> ;NEJM Evidence. 2022 Jul 1
9 citations
Navigating a newly diagnosed cancer through clinician-facilitated discussions of health-related patient values: a qualitative analysis.
Kathleen A Lynch, Camila Bernal, Danielle R Romano, Paul Shin, Judith E Nelson, Molly Okpako, Kelley Anderson, Elizabeth Cruz, Anjali V Desai, Virginia M Klimek, Andre...> ;BMC Palliative Care. 2022 Mar 6
2 citations
TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes.
Mariko Yabe, Aidana Z. Omarbekova, Meier Hsu, Hannah May, Maria E. Arcila, Ying Liu, Ahmet Dogan, Andrew M. Brunner, Valentina Nardi, Robert P. Hasserjian, Virginia M....> ;Cancers. 2021 Nov 2
4 citations
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
Rami S. Komrokji, Megan Melody, Najla Al Ali, Onyee Chan, Virginia M. Klimek, Brian Ball, Mikkael A. Sekeres, George W. Lucas, Jaroslaw P. Maciejewski, David A. Sallma...> ;Leukemia & Lymphoma. 2021 Aug 27
3 citations
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challeng...
Erica D. Warlick, Celalettin Ustun, Astrid Andreescu, Anthony F. Bonagura, Andrew M. Brunner, Abhinav B. Chandra, James M. Foran, Mark B. Juckett, Tamila L. Kindwall-K...> ;Cancer. 2021 Aug 10
The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant
Ana Alarcon Tomas, Karissa Whiting, Molly Maloy, Josel D. Ruiz, Sean M. Devlin, Miriam Sanchez-Escamilla, Lucrecia Yáñez, Nerea Castillo, Martina Pennisi, Christina Ch...> ;Bone Marrow Transplantation. 2021 Jul 12
80 citations
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Ades,...> ;Leukemia. 2021 Jun 25
1 citations
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Juan S Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca ...> ;Nature Medicine. 2021 May 1
1 citations
Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitative Study.
Anjali V. Desai, Virginia M. Klimek, Peter J. Wan, Aileen Heinberg, Kelley L Anderson, Camila Bernal, Judith E Nelson> ;BMJ Supportive & Palliative Care. 2021 Apr 26
1 citations
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Juan S Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca ...> ;Nature Medicine. 2021 Mar 1
53 citations
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Teng Gao, Ryan Ptashkin, Kelly L. Bolton, Maria Sirenko, Christopher J. Fong, Barbara Spitzer, Kamal Menghrajani, Juan E. Arango Ossa, Yangyu Zhou, Elsa Bernard, Max L...> ;Nature Communications. 2021 Jan 12
281 citations
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton, Ryan Ptashkin, Teng Gao, Lior Z. Braunstein, Sean M. Devlin, Daniel Kelly, Minal Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine C. Co...> ;Nature Genetics. 2020 Oct 26
307 citations
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan S. Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Lu...> ;Nature Medicine. 2020 Aug 3
8 citations
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-cent...
Justin Taylor, Xiaoli Mi, Alexander V Penson, Stella V Paffenholz, Kelsey Alvarez, Allison Sigler, Stephen S. Chung, Raajit K. Rampal, Jae H. Park, Eytan M. Stein, Mar...> ;The Lancet. Haematology. 2020 Aug 1
1 citations
A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients.
Katie L. Thoren, Scott T. Avecilla, Virginia M. Klimek, Cheryl Goss> ;Transfusion. 2020 Jan 23
5 citations
Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes
Tingting Qin, Jason Sotzen, Raajit K. Rampal, Franck Rapaport, Ross L. Levine, Virginia M. Klimek, Stephen D. Nimer, Maria E. Figueroa> ;Leukemia. 2019 Jul 22
12 citations
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
Wenbin Xiao, Aaron D Goldberg, Christopher Famulare, Sean M. Devlin, Nghia T. Nguyen, Sinnifer Sim, Charlene C. Kabel, Minal Patel, Erin McGovern, Akshar Patel, Jessic...> ;Haematologica. 2019 Jul 1
Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.
Zachary D. Epstein-Peterson, Sean M. Devlin, Eytan M. Stein, Virginia M. Klimek, Leonard B. Saltz, Martin S. Tallman> ;Leukemia Research. 2019 Jul 1
7 citations
End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.
Richard J. Lin, Theresa A. Elko, Miguel-Angel Perales, Koshy Alexander, Ann A. Jakubowski, Sean M. Devlin, Parastoo B. Dahi, Esperanza B. Papadopoulos, Virginia M. Kli...> ;Bone Marrow Transplantation. 2019 May 1
45 citations
Managing Clonal Hematopoiesis in Patients With Solid Tumors.
Kelly L. Bolton, Nancy K. Gillis, Catherine C. Coombs, Koichi Takahashi, Ahmet Zehir, Rafael Bejar, Guillermo Garcia-Manero, Andrew Futreal, Brian C. Jensen, Luis A. D...> ;Journal of Clinical Oncology. 2019 Jan 1
24 citations
1-2-3 Project: A Quality Improvement Initiative to Normalize and Systematize Palliative Care for All Patients With Cancer in the Outpatient Clinic Setting.
Anjali V. Desai, Virginia M. Klimek, Kimberly Chow, Andrew S. Epstein, Camila Bernal, Kelly Anderson, Molly Okpako, Robin Rawlins-Duell, Dana Kramer, Danielle R. Roman...> ;Journal of Oncology Practice. 2018 Dec 11
10 citations
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, H...> ;Haematologica. 2018 Nov 1
27 citations
Micafungin Versus Posaconazole Prophylaxis in Acute Leukemia or Myelodysplastic Syndrome: A Randomized Study
David J Epstein, Susan K. Seo, Yao-Ting Huang, Jay H. Park, Virginia M. Klimek, Ellin Berman, Martin S. Tallman, Mark G. Frattini, Genovefa A. Papanicolaou> ;The Journal of Infection. 2018 May 7
329 citations
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Michael Seiler, Akihide Yoshimi, Rachel Darman, Betty Chan, Keaney Gregg F, Michael P. Thomas, Anant A. Agrawal, Benjamin Caleb, Alfredo Csibi, Eckley Sean, Peter Fekk...> ;Nature Medicine. 2018 Feb 19
Join now to see all

Journal Articles

End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center
Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018